FrancophonIA/ELRC3.0 huggingface dataset:
English: Emtricitabine /Tenofovir disoproxil Zentiva 200 mg/245 mg film-coated tablets are blue, oval biconvex film coated tablet without half-score with dimensions approx. 19.35 x 9.75 mm.
Slovenian: Izgled zdravila Emtricitabin/dizoproksiltenofovirat Zentiva in vsebina pakiranja Emtricitabin/ dizoproksiltenofovirata Zentiva 200 mg/245 mg filmsko obložena tablete so modre, ovalne, bikonveksne filmsko obložena tablete brez razdelilne zareze z dimenzijami približno 19,35 x 9,75 mm.
English: Emtricitabine/ tenofovir disoproxil (n = 1,579)
Slovenian: Emtricitabin/dizop roksiltenofovirat (n = 1.579)
English: Nervous system disorders Very common headache dizziness
Slovenian: Bolezni živčevja Zelo pogosto glavobol omotičnost
English: Each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 291.5 mg of tenofovir disoproxil phosphate or 136 mg of tenofovir).
Slovenian: Ena filmsko obložena tableta vsebuje 200 mg emtricitabina in 245 mg dizoproksiltenofovirata (kar je ekvivalentno 291,5 mg dizoproksiltenofovirijevega fosfata ali 136 mg tenofovirja).
English: When missing data were excluded, 91% of patients in the tenofovir disoproxil treatment group and 94% of patients in the stavudine or zidovudine treatment group had HIV-1 RNA concentrations < 400 copies/ml at week 48.
Slovenian: Po izključitvi manjkajočih podatkov je imelo v 48. tednu 91 % bolnikov v skupini, zdravljeni z dizoproksiltenofoviratom, in 94 % bolnikov v skupini, zdravljeni s stavudinom ali zidovudinom, koncentracije HIV-1 RNA < 400 kopij/ml.
English: • vancomycin (for bacterial infection).
Slovenian: • vankomicin (za bakterijsko okužbo)
English: In patients who received treatment with tenofovir disoproxil, or stavudine or zidovudine, mean lumbar spine BMD Z-score was -1.034 and -0.498, and mean total body BMD Z-score was -0.471 and -0.386, respectively, at baseline.
Slovenian: Pri bolnikih, ki so dobivali dizoproksiltenofovirat ali stavudin ali zidovudin, je bila ob izhodišču povprečna Z-vrednost MGK ledvene hrbtenice -1,034 oz. -0,498 in povprečna Z-vrednost MGK za celo telo -0,471 oz. -0,386.
English: Following oral administration of emtricitabine/tenofovir disoproxil to healthy subjects, emtricitabine and tenofovir disoproxil are rapidly absorbed and tenofovir disoproxil is converted to tenofovir.
Slovenian: Pri zdravih osebah se po peroralnem vnosu emtricitabina / dizoproksiltenofovirata emtricitabin in dizoproksiltenofovirat hitro absorbirata in dizoproksiltenofovirat se pretvori v tenofovir.
English: In the iPrEx clinical study, no HIV-1 variants expressing K65R, K70E, M184V, or M184I were detected at the time of seroconversion among subjects who became infected with HIV-1 after enrollment in the study.
Slovenian: V klinični študiji iPrEx ni bila zaznana nobena različica HIV-1 z izraženo K65R, K70E, M184V ali M184I v času serokonverzije pri osebah, ki so se okužile s HIV-1 po vključitvi v študijo.
English: Gastrointestinal disorders Very common diarrhoea, nausea diarrhoea, vomiting, nausea
Slovenian: Bolezni prebavil Zelo pogosto driska, navzea driska, bruhanje, navzea
English: In study GS-US-104-0321, 87 HIV-1 infected treatment-experienced patients 12 to < 18 years of age were treated with tenofovir disoproxil (n = 45) or placebo (n = 42) in combination with an optimised background regimen (OBR) for 48 weeks.
Slovenian: V študiji GS-US-104-0321 se je 87 predhodno zdravljenih bolnikov, okuženih s HIV-1, starih od 12 do < 18 let, 48 tednov zdravilo z dizoproksiltenofoviratom (n = 45) ali placebom (n = 42) v kombinaciji z optimiranim osnovnim režimom (OOR).
English: The use of Emtricitabine/Tenofovir disoproxil Zentiva is not recommended in individuals under the age of 18 years with renal impairment (see sections 4.2 and 4.4).
Slovenian: Uporabe zdravila Emtricitabin/dizoproksiltenofovirat Zentiva se ne priporoča pri posameznikih, starih manj kot 18 let, z ledvično okvaro (glejte poglavji 4.2 in 4.4).
English: Emtricitabine/Tenofovir disoproxil Zentiva should be initiated by a physician experienced in the management of HIV infection.
Slovenian: Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva mora uvesti zdravnik, ki že ima izkušnje z zdravljenjem okužbe z virusom HIV.
English: Emtricitabine/Tenofovir disoproxil Zentiva should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).
Slovenian: Uporabi zdravila Emtricitabin/dizoproksiltenofovirat Zentiva se je treba izogniti pri predhodno zdravljenih bolnikih, okuženih s HIV-1, ki so nosilci mutacije K65R (glejte poglavje 5.1).
English: Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).
Slovenian: Zaščita pred izpostavitvijo (Pre-exposure prophylaxis - PrEP) Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva je indicirano za zaščito pred izpostavitvijo, ob hkratnem upoštevanju varnega spolnega vedenja za zmanjšanje tveganja za spolno pridobljeno okužbo z virusom HIV-1 pri odraslih in mladostnikih z visokim tveganjem (glejte poglavja 4.2, 4.4 in 5.1).
English: • That Emtricitabine/Tenofovir disoproxil Zentiva is not recommended for use in paediatric patients with renal impairment
Slovenian: • da se zdravila Emtricitabin/dizoproksiltenofovirat Zentiva pri pediatričnih bolnikih z ledvično okvaro ne priporoča;
English: Do not stop taking Emtricitabine/Tenofovir disoproxil Zentiva without contacting your doctor.
Slovenian: Zdravila Emtricitabin/dizoproksiltenofovirat Zentiva ne prenehajte jemati, ne da bi se pred tem posvetovali z zdravnikom.
English: Cmin: ↑ 51% (↑ 37 to ↑ 66)
Slovenian: Cmin: ↑ 51% (↑ 37 do ↑ 66)
English: • Reminders on what the individual should know before and while taking Emtricitabine/Tenofovir disoproxil Zentiva to reduce the risk of getting HIV infection
Slovenian: • opozorila, kaj mora pred in med jemanjem zdravila Emtricitabin/dizoproksiltenofovirat Zentiva vedeti posameznik, da se zmanjša tveganje za okužbo s HIV;
English: Outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 3 bottles of 30 film-coated tablets.
Slovenian: Škatle z 1 plastenko s 30 filmsko obloženimi tabletami in škatle z 3 plastenkami s 30 filmsko obloženimi tabletami.
English: AUC: ↓ 12% (↓ 16 to ↓ 8) Cmax: ↓ 16% (↓ 22 to ↓ 10) Cmin: ↓ 15% (↓ 12 to ↓ 9)
Slovenian: AUC: ↓ 12% (↓ 16 do ↓ 8) Cmax: ↓ 16% (↓ 22 do ↓ 10) Cmin: ↓ 15% (↓ 12 do ↓ 9)
English: There are no data on the long term renal and bone effects of emtricitabine/tenofovir disoproxil when used for pre-exposure prophylaxis in uninfected adolescents (see section 5.1).
Slovenian: Podatkov o dolgoročnih učinkih zdravila Emtricitabin/dizoproksiltenofovirat Zentiva na ledvice in kosti ob zaščiti pred izpostavitvijo pri neokuženih mladostnikih ni (glejte poglavje 5.1).
English: Rare lactic acidosis
Slovenian: Redko laktacidoza
English: Cmin: ↑ 39% (↑ 20 to ↑ 61)
Slovenian: Cmin: ↑ 39% (↑ 20 do ↑ 61)
English: Emtricitabine/ tenofovir disoproxil (n = 1251)
Slovenian: Emtricitabin/dizo proksiltenofovirat (n = 1.251)
English: If vomiting occurs more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Zentiva a second dose should not be taken.
Slovenian: Če pride do bruhanja več kot 1 uro po jemanju zdravila Emtricitabin/dizoproksiltenofovirat Zentiva, se ne sme vzeti drugega odmerka.
English: 30 film-coated tablets 90 (3 bottles of 30) film-coated tablets
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA filmsko obložena tableta 30 filmsko obloženih tablet 90 (3 plastenke s 30) filmsko obloženih tablet
English: While taking Emtricitabine/Tenofovir disoproxil Zentiva to treat HIV or to reduce the risk of getting HIV:
Slovenian: Če zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva jemljete za zdravljenje okužbe s HIV ali za zmanjšanje tveganja za okužbo s HIV:
English: Sofosbuvir/velpatasvir/ voxilaprevir (400 mg/100 mg/100 mg+100 mg q.d.
Slovenian: sofosbuvir/velpatasvir voksilaprevir (400 mg/100 mg/ 100 mg+100 mg enkrat dnevno)3 +
English: In the Partners PrEP clinical study, no HIV 1 variants expressing K65R, K70E, M184V, or M184I were detected at the time of seroconversion among subjects who became infected with HIV-1 during the study.
Slovenian: V klinični študiji Partners PrEP niso bile zaznane nobene različice HIV-1 z izraženo K65R, K70E, M184V ali M184I v času serokonverzije pri osebah, ki so se okužile s HIV-1 med študijo.
English: ORAL CONTRACEPTIVES Norgestimate/ethinyl oestradiol/tenofovir disoproxil
Slovenian: PERORALNI KONTRACEPTIVI norgestimat/etinilestradiol/diz oproksiltenofovirat norgestimat:
English: Skin and subcutaneous tissue disorders Very common rash
Slovenian: Bolezni kože in podkožja Zelo pogosto izpuščaj
English: Emtricitabine/Tenofovir disoproxil Zentiva 200 mg/245 mg film-coated tablets Emtricitabine/tenofovir disoproxil
Slovenian: Emtricitabin/dizoproksiltenofovirat Zentiva 200 mg/245 mg filmsko obložene tablete emtricitabin/dizoproksiltenofovirat
English: Involved in Transactional Sex Last 6 Month, N (%) Known HIV+ Partner Last 6 Months, N (%) Syphilis Seroreactivity, N (%) Serum Herpes Simplex Virus Type 2 Infection, N (%) Urine Leukocyte Esterase Positive, N (%) URAI = unprotected receptive anal intercourse
Slovenian: Serumska okužba z virusom herpes simpleksa tipa 2, N (%) Pozitivna prisotnost levkocita esteraza v urinu, N (%) URAI = nezaščiten receptivni analni spolni odnos
English: Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosinerelated adverse reactions.
Slovenian: Sočasna uporaba dizoproksiltenofovirata in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za 40-60%, kar lahko poveča tveganje pojava neželenih učinkov, povezanih z didanozinom.
English: Emtricitabine/Tenofovir disoproxil Zentiva should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4).
Slovenian: Zdravila Emtricitabin/dizoproksiltenofovirat Zentiva se ne sme sočasno uporabljati z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat, tenofoviralafenamid ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.4).
English: Common pain, asthenia 1 This adverse reaction may occur as a consequence of proximal renal tubulopathy.
Slovenian: 1 Ta neželeni učinek se lahko pojavi kot posledica proksimalne ledvične tubulopatije.
English: • If renal abnormalities are detected or suspected then consultation with a nephrologist should be obtained to consider interruption of Emtricitabine/Tenofovir disoproxil Zentiva treatment
Slovenian: • Ob odkritju nenormalnega delovanja ledvic ali sumu nanje se je treba posvetovati z nefrologom in razmisliti o prekinitvi zdravljenja z zdravilom Emtricitabin/dizoproksiltenofovirat Zentiva;
English: How to store Emtricitabine/Tenofovir disoproxil Zentiva Contents of the pack and other information
Slovenian: Shranjevanje zdravila Emtricitabin/dizoproksiltenofovirat Zentiva Vsebina pakiranja in dodatne informacije
English: Renal and urinary disorders Uncommon increased creatinine, proteinuria, proximal renal tubulopathy including Fanconi syndrome
Slovenian: Bolezni sečil Občasno povišan kreatinin, proteinurija, proksimalna ledvična tubulopatija, vključujoč Fanconijev sindrom
English: Emtricitabine/Tenofovir disoproxil Zentiva should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5).
Slovenian: Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva se ne sme dajati skupaj z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat, tenofoviralafenamid ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.5).
English: NARCOTIC ANALGESICS Methadone/tenofovir disoproxil
Slovenian: NARKOTIČNI ANALGETIKI metadon/dizoproksiltenofovir at metadon:
English: It is preferable that Emtricitabine/Tenofovir disoproxil Zentiva is taken with food.
Slovenian: Priporočljivo je, da se zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva jemlje s hrano.
English: Tablet core: microcrystalline cellulose, croscarmellose sodium, talc, hydrophobic colloidal silica, magnesium stearate.
Slovenian: Jedro tablete mikrokristalna celuloza natrijeva kroskarmeloza smukec hidrofobni koloidni silicijev dioksid magnezijev stearat
English: • Do not breast-feed during treatment with Emtricitabine/Tenofovir disoproxil Zentiva.
Slovenian: • Med zdravljenjem z zdravilom Emtricitabin/dizoproksiltenofovirat Zentiva ne dojite.
English: • That use of Emtricitabine/Tenofovir disoproxil Zentiva should be avoided with concomitant or recent use of nephrotoxic medicinal products.
Slovenian: • da se je treba uporabi zdravila Emtricitabin/dizoproksiltenofovirat Zentiva izogniti, če bolnik sočasno jemlje ali je predhodno jemal nefrotoksična zdravila.
English: Outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets.
Slovenian: Škatle z 1 plastenko s 30 filmsko obloženimi tabletami in škatle z 90 (3 plastenke s 30) filmsko obloženimi tabletami.
English: ANTI-INFECTIVES Hepatitis B virus (HBV) antiviral agents Adefovir dipivoxil /tenofovir disoproxil
Slovenian: ZDRAVILA ZA ZDRAVLJENJE OKUŽB Protivirusna zdravila za zdravljenje hepatitisa B (HBV) dipivoksiladefovirat/dizoprok siltenofovirat dipivoksiladefovirat:
English: In patients who received treatment with tenofovir disoproxil or placebo, mean lumbar spine BMD Zscore was -1.004 and -0.809, and mean total body BMD Z-score was -0.866 and -0.584, respectively, at baseline.
Slovenian: Pri bolnikih, ki so dobivali dizoproksiltenofovirat ali placebo, je bila ob izhodišču povprečna Zvrednost MGK ledvene hrbtenice -1,004 oz. -0,809, in povprečna Z-vrednost MGK za celo telo0,866 oz. -0,584.
English: • ganciclovir (for viral infection).
Slovenian: • ganciklovir (za virusno okužbo)
English: Renal safety with emtricitabine/tenofovir disoproxil has only been studied to a very limited degree in HIV-1 infected patients with impaired renal function (creatinine clearance < 80 ml/min).
Slovenian: Varnost emtricitabina/dizoproksiltenofovirata za ledvice pri bolnikih z ledvično okvaro (očistek kreatinina < 80 ml/min), okuženih s HIV-1, so preučevali v zelo omejenem obsegu.
English: Common dizziness headache
Slovenian: Pogosto omotičnost glavobol
English: HIV-1 infection
Slovenian: Okužba s HIV-1
English: Co-administration of tenofovir disoproxil and didanosine is not recommended as it results in a 40 - 60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Slovenian: Sočasna uporaba dizoproksiltenofovirata in didanozina Sočasna uporaba ni priporočena, ker povzroča povečanje sistemske izpostavljenosti didanozinu za 40-60 %, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
English: The mean (%CV) tenofovir drug exposure increased from 2,185 (12%) ng·h/ml in subjects with normal renal function, to 3,064 (30%) ng·h/ml, 6,009 (42%) ng·h/ml and 15,985 (45%) ng·h/ml, in subjects with mild, moderate and severe renal impairment, respectively.
Slovenian: Pri bolnikih z normalno ledvično funkcijo s srednjo vrednostjo (% koeficienta variacije) izpostavljenosti tenofovirju 2.185 (12%) ng h/ml se je le-ta pri bolnikih z blago ledvično okvaro zvišala na 3.064 (30%) ng h/ml, pri bolnikih z zmerno ledvično okvaro na 6.009 (42%) ng h/ml in na 15.985 (45%) ng h/ml pri bolnikih s hudo ledvično okvaro.
English: The mean (%CV) emtricitabine drug exposure increased from 12 (25%) μg·h/ml in subjects with normal renal function, to 20 (6%) μg·h/ml, 25 (23%) μg·h/ml and 34 (6%) μg·h/ml, in subjects with mild, moderate and severe renal impairment, respectively.
Slovenian: Pri osebah z normalno ledvično funkcijo s srednjo vrednostjo (% koeficienta variacije) izpostavljenosti emtricitabinu 12 (25 %) μg•h/ml se je le-ta pri bolnikih z blago ledvično okvaro zvišala na 20 (6 %) μg•h/ml, pri osebah z zmerno ledvično okvaro na 25 (23 %) μg h/ml in na 34 (6 %) μg•h/ml pri bolnikih s hudo ledvično okvaro.
English: GS-3310072: AUC: ↔
Slovenian: GS-3310072: AUC: ↔ Cmax: ↔ Cmin: ↔
English: Uncommon anaemia2
Slovenian: Občasno anemija2
English: If renal abnormalities are suspected or detected then consultation with a nephrologist should be obtained to consider interruption of Emtricitabine/Tenofovir disoproxil Zentiva use.
Slovenian: Ob odkritju nenormalnega delovanja ledvic ali sumu nanj se je treba posvetovati z nefrologom in razmisliti o prekinitvi uporabe zdravila Emtricitabin/dizoproksiltenofovirat Zentiva.
English: Only samples from subjects randomized to emtricitabine/tenofovir disoproxil were evaluated for detectable plasma or intracellular tenofovir disoproxil-DP levels.
Slovenian: Samo vzorci oseb, ki so randomizirano prejemale zdravilo emtricitabin/dizoproksiltenofovirat, so bili ocenjeni glede zaznanih koncentracij dizoproksiltenofovirata-DP v plazmi ali znotraj celic.
English: At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA < 50 copies/ml with the once and twice daily regimens of lopinavir/ritonavir, respectively.
Slovenian: V 48. tednu je 70% bolnikov v režimu zdravljenja z lopinavirjem/ritonavirjem enkrat na dan in 64% bolnikov v režimu zdravljenja z lopinavirjem/ritonavirjem dvakrat na dan izkazalo HIV-1 RNA < 50 kopij/ml.
English: A decreased dosage of 250 mg didanosine coadministered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.
Slovenian: Sočasna uporaba zmanjšanega odmerka didanozina (250 mg) in zdravljenje z dizoproksiltenofoviratom je bilo v več preizkušenih kombinacijah za zdravljenje okužbe z virusom HIV-1 povezano s poročili o visoki stopnji virološke odpovedi.
English: Emtricitabine/Tenofovir disoproxil Zentiva 200 mg / 245 mg film-coated tablets
Slovenian: IME ZDRAVILA Emtricitabin/dizoproksiltenofovirat Zentiva 200 mg/245 mg filmsko obložene tablete
English: • amphotericin B (for fungal infection).
Slovenian: • amfotericin B (za glivično okužbo)
English: • decreases in potassium in the blood,
Slovenian: • zmanjšanje količine kalija v krvi,
English: If serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving emtricitabine/tenofovir disoproxil, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Slovenian: Če je potrjena vrednost serumskega fosfata < 3,0 mg/dl (0,96 mmol/l) pri katerem koli pediatričnem bolniku, ki dobiva emtricitabin/dizoproksiltenofovirat, je treba ponovno ovrednotiti ledvično funkcijo v roku enega tedna, vključno z merjenjem koncentracije glukoze in kalija v krvi ter glukoze v urinu (glejte poglavje 4.8, proksimalna tubulopatija).
English: • Provides information on how to store Emtricitabine/Tenofovir disoproxil Zentiva.
Slovenian: • nudi informacije o tem, kako jemati zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva;
English: Renal adverse reactions consistent with proximal renal tubulopathy have been reported in HIV-1 infected paediatric patients aged 2 to < 12 years in clinical study GS-US-104-0352 (see sections 4.8 and 5.1).
Slovenian: Pri pediatričnih bolnikih, starih od 2 do < 12 let, okuženih s HIV-1, so v klinični študiji GS-US104-0352 poročali o neželenih učinkih na ledvice, skladnih s proksimalno renalno tubulopatijo (glejte poglavji 4.8 in 5.1).
English: HIV-1 infected patients receiving Emtricitabine/Tenofovir disoproxil Zentiva or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Slovenian: Pri bolnikih s HIV-1, ki se zdravijo z zdravilom Emtricitabin/dizoproksiltenofovirat Zentiva ali s katero koli drugo obliko protiretrovirusne terapije, lahko še vedno pride do oportunistične okužbe in drugih zapletov okužbe z virusom HIV.
English: • aminoglycosides (for bacterial infection).
Slovenian: • aminoglikozidi (za bakterijsko okužbo)
English: Individuals should be re-confirmed to be HIV negative at frequent intervals (e.g. at least every 3 months) using a combined antigen/antibody test while taking Emtricitabine/Tenofovir disoproxil Zentiva for pre-exposure prophylaxis.
Slovenian: Za zaščito pred izpostavitvijo je treba med jemanjem zdravila Emtricitabin/dizoproksiltenofovirat Zentiva pri posameznikih redno (npr. najmanj vsake 3 mesece) ponovno potrditi, da so HIV negativni, z uporabo kombiniranega testa na antigen/protitelesa.
English: Emtricitabine/ tenofovir disoproxil/ efavirenz*
Slovenian: Emtricitabin/ dizoproksiltenof ovirat / efavirenz*
English: Metabolism and nutrition disorders Very common hypophosphataemia1
Slovenian: Bolezni imunskega sistema Pogosto alergijska reakcija Presnovne in prehranske motnje Zelo pogosto hipofosfataemija1
English: • That if serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving tenofovir disoproxil, renal function should be re-evaluated within one week.
Slovenian: • da je treba po enem tednu delovanje ledvic ponovno oceniti, če so potrjene vrednosti serumskega fosfata < 3,0 mg/dl (0,96 mmol/l) pri vsakem pediatričnem bolniku, ki dobiva dizoproksiltenofovirat;
English: Recommendation concerning co-administration with Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Slovenian: Priporočilo glede sočasne uporabe z zdravilom Emtricitabin/dizoproksiltenofovi rat Zentiva (emtricitabin 200 mg, dizoproksiltenofovirat 245 mg)
English: AUC: ↑96% (↑74 to ↑121) Cmax: ↑68% (↑54 to ↑84) Cmin: ↑118% (↑91 to ↑150)
Slovenian: AUC: ↑ 96 % (↑ 74 do ↑ 121) Cmax: ↑ 68 % (↑ 54 do ↑ 84) Cmin: ↑ 118 % (↑ 91 do ↑ 150)
English: • foscarnet (for viral infection).
Slovenian: • foskarnet (za virusno okužbo)
English: 2 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients.
Slovenian: 2 Pri pediatričnih bolnikih je bila ob jemanju emtricitabina anemija pogosta in sprememba obarvanosti kože
English: Do not stop taking Emtricitabine/Tenofovir disoproxil Zentiva
Slovenian: Ne prenehajte jemati zdravila Emtricitabin/dizoproksiltenofovirat Zentiva
English: AUC: ↓ 4% (↓ 9 to ↑ 0) Cmax: ↓ 6% (↓ 13 to ↑ 0) Cmin: ↓ 2% (↓ 9 to ↑ 6)
Slovenian: AUC: ↓ 4% (↓ 9 do ↑ 0) Cmax: ↓ 6% (↓ 13 do ↑ 0) Cmin: ↓ 2% (↓ 9 do ↑ 6)
English: Tenofovir: AUC: ↑50% (↑ 42 to ↑ 59)
Slovenian: tenofovir: AUC: ↑ 40 % (↑ 34 do↑ 45)
English: AUC: ↑ 22% Cmin: ↑ 37%
Slovenian: AUC: ↑ 22%
English: Table 1: Dosing recommendations in adults with renal impairment Treatment of HIV-1 infection Pre-exposure prophylaxis
Slovenian: Preglednica 1: Priporočeno odmerjanje pri odraslih z ledvično okvaro
English: IMMUNOSUPPRESSANTS Tacrolimus/tenofovir disoproxil /emtricitabine
Slovenian: IMUNOSUPRESIVI takrolimus/dizoproksiltenofov irat/emtricitabin takrolimus:
English: Therefore Emtricitabine/Tenofovir disoproxil Zentiva should not be used during breast-feeding.
Slovenian: Zato se zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva med dojenjem ne sme uporabljati.
English: AUC: ↑ 32% (↑ 25 to ↑ 38) Cmax: ↔
Slovenian: AUC: ↑ 32% (↑ 25 do ↑ 38) Cmax: ↔
English: • It is also used to treat HIV in adolescents aged 12 to less than 18 years who weigh at least
Slovenian: • Uporablja se tudi za zdravljenje okužbe z virusom HIV pri mladostnikih, starih 12 let do manj kot 18 let, s telesno maso vsaj 35 kg, ki so se predhodno že zdravili z drugimi zdravili za zdravljenje okužbe s HIV, ki pa več ne učinkujejo ali so povzročila neželene učinke.
English: AUC: ↑ 6% (↓ 1 to ↑ 13) Cmax: ↑13% (↑ 1 to ↑ 27)
Slovenian: AUC: ↑ 6% (↓ 1 do ↑ 13) Cmax: ↑13% (↑ 1 do ↑ 27) Cmin: n/i